News & Comment

Filter By:

  • Gilgamesh Pharmaceuticals is developing a diverse portfolio of novel, potentially first-in-class and best-in-class medicines targeting mechanisms with demonstrated profound efficacy (onset duration and/or prolonged treatment duration) in humans for the treatment of mental health disorders.

    • Gilgamesh Pharmaceuticals
    Advertisement Feature
  • PsychoGenics uses a high-throughput platform comprising cameras and AI to analyze the behaviors of mice given a drug candidate before comparing them to a reference database. The platform enables the development of novel neuropsychiatric drugs and accelerates drug discovery.

    • PsychoGenics
    Advertisement Feature
  • Voyager Therapeutics is unlocking the potential of adeno-associated virus gene therapy to treat a range of neurological disorders, broadening the therapeutic window while ensuring efficacy and safety.

    • Voyager Therapeutics
    Advertisement Feature
  • Praxis Precision Medicines, Inc. uses a genetics-driven approach to develop potential best-in-class drugs for patients with central nervous system (CNS) disorders that are characterized by faulty electrical activity in the brain.

    • Praxis Precision Medicines, Inc.
    Advertisement Feature
  • Established by Nature Awards in partnership with Merck, The Spinoff Prize showcases global excellence in the commercialisation of research through the creation of university spinoff companies.

    • Biopharma Dealmakers
    News
  • Glyscend Therapeutics is developing first-in-class polymer drugs that uniquely interact with the gut wall to treat metabolic and chronic conditions. The company’s lead candidate, GLY-200, is advancing into phase 2 clinical studies for the treatment of type 2 diabetes.

    • Glyscend, Inc.
    Advertisement Feature
  • EraCal Therapeutics is developing a novel oral-active anti-obesity drug, Era-379, identified using the company’s state-of-the-art, zebrafish-based platform technology. EraCal is raising a series A to generate human proof-of-concept data for Era-379 and expanding its portfolio through co-development partnerships.

    • EraCal Therapeutics Ltd.
    Advertisement Feature
  • With siRNA-based drugs becoming established as a therapeutic modality, large companies are engaging in the field through deals and acquisitions, and cardiovascular and metabolic diseases are among their targets.

    • Biopharma Dealmakers
    News Feature
  • Orthogon Therapeutics is developing first-in-class anti-infective small molecule drugs using biophysics- and structure-based drug design to optimize compounds that target difficult-to-drug proteins. The company’s initial focus is on treating BK and JC polyomavirus infections in transplant patients.

    • Orthogon Therapeutics, LLC
    Advertisement Feature
  • The emergence of COVID-19 sparked a huge increase in the volume of infectious disease deals in 2020, but how has the market fared in the past year?

    • Biopharma Dealmakers
    • DealForma, LLC
    News Feature
  • HOOKIPA Pharma is developing a new class of arenavirus-based immunotherapies that activate and amplify targeted T cells to fight cancer. The company is seeking development and commercialization partners for several of its preclinical and clinical programs.

    • Hookipa Pharma Inc.
    Advertisement Feature
  • Chimeron Bio aims to transform RNA therapy with its novel nanoparticle technology by developing new vaccines and therapies based on self-amplifying RNA for the treatment of infectious diseases, oncology and rare genetic disorders.

    • Chimeron Bio
    Advertisement Feature